Plain-English translation of NCT04804644 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a focused radiation treatment that targets only the spots where cancer has spread to the brain works as well as (or better than) radiation to the entire brain, combined with memantine. The main goal is to find out which approach better protects your memory and thinking skills after treatment, since both radiation methods can sometimes affect how well your brain works.
Both radiation approaches can effectively treat brain cancer, but they carry a risk of affecting memory and cognitive function. This trial exists to determine whether the focused approach can achieve the same cancer control as whole-brain radiation while reducing the risk to your thinking and memory.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment groups. One group receives focused radiation therapy delivered in one or a few sessions. The other group receives whole-brain radiation treatment over 2 weeks, plus a medication (memantine) taken daily for up to 24 weeks. In both groups, you will have MRI scans and blood tests throughout the study to monitor how well the treatment is working and how it affects your memory and thinking. You will also complete memory and thinking tests at various points during and after treatment.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States